Form 4: Zimmer Biomet Director Maria Teresa Hilado Reports Significant Equity Award Acquisitions

Zimmer Biomet Holdings, Inc. Director Maria Teresa Hilado reported the acquisition of 810.46 phantom stock units and 1,404.798 restricted stock units on May 29, 2025, increasing her beneficial ownership in the company.

Summary

• Maria Teresa Hilado, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported changes in her beneficial ownership through a Form 4 filing.
• On May 29, 2025, she acquired 810.46 phantom stock units at a conversion price of $92.54 per unit. These units were accrued under the company's Deferred Compensation Plan for Non-Employee Directors.
• The phantom stock units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which her service as a Director ceases.
• Her total beneficial ownership of phantom stock units after this transaction is 10,134.921, which includes 21.839 units accrued on April 30, 2025, from dividend reinvestment.
• Additionally, on May 29, 2025, she acquired 1,404.798 Restricted Stock Units (RSUs). These RSUs are immediately 100% vested.
• The Restricted Stock Units are subject to mandatory deferral until the later of her termination of service as a Director or three years after the grant date.
• Her total beneficial ownership of Restricted Stock Units after this transaction is 7,580.726, which includes units granted in prior years with different deferral periods.

Sentiment

Score: 7

Explanation: The filing indicates a director's continued accumulation of equity, aligning their interests with shareholders, which is generally positive. It's a routine compensation report, so the sentiment is neutral to slightly positive due to insider ownership increase.

Positives

• The acquisition of phantom stock units and restricted stock units by a director indicates continued alignment of interests between management and shareholders.
• The immediate 100% vesting of the Restricted Stock Units suggests a strong commitment from the company to its directors and serves as an incentive for long-term service.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it primarily reports compensation-related equity awards.

Risks

• No specific risks are mentioned in this Form 4 filing, which is typical for this type of document.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook, as its purpose is solely to report changes in beneficial ownership related to director compensation.

Industry Context

This filing is a routine disclosure of director compensation in the form of equity awards, common across publicly traded companies. It reflects standard corporate governance practices for aligning director incentives with shareholder value, typical within the medical device industry where Zimmer Biomet operates.

Comparison to Industry Standards

• The compensation structure involving phantom stock units and restricted stock units is a common practice for non-employee directors in large medical device companies, similar to those observed at peers like Stryker Corporation (SYK), Johnson & Johnson (JNJ) (through its MedTech segment), and Medtronic plc (MDT).
• The immediate vesting of RSUs with a deferral period is a standard mechanism to ensure long-term alignment while managing tax implications for directors.
• The specific values of units granted are commensurate with director compensation packages at companies of similar market capitalization and industry standing.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of additional equity by a director increases their alignment with shareholder interests, potentially fostering more shareholder-friendly decision-making.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The document does not outline specific future actions or milestones for the company, as it is a disclosure of past transactions related to director compensation.

Key Dates

Recommendation

Keywords

Zimmer Biomet Holdings, ZBH, SEC Form 4, Insider Trading, Phantom Stock Units, Restricted Stock Units, Director Compensation, Equity Awards, Beneficial Ownership, Maria Teresa Hilado